Stokes Family Office LLC Invests $465,000 in Sanofi (NASDAQ:SNY)

Stokes Family Office LLC acquired a new stake in Sanofi (NASDAQ:SNYFree Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 9,635 shares of the company’s stock, valued at approximately $465,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of SNY. Charles Schwab Investment Management Inc. lifted its holdings in shares of Sanofi by 31.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares during the period. Arkadios Wealth Advisors grew its holdings in Sanofi by 19.0% during the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock worth $227,000 after acquiring an additional 751 shares during the period. Geode Capital Management LLC raised its position in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock worth $14,681,000 after acquiring an additional 16,780 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Sanofi by 20.9% in the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares during the period. Finally, Kentucky Trust Co purchased a new stake in shares of Sanofi during the 4th quarter worth $436,000. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on SNY shares. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Sanofi has a consensus rating of “Buy” and an average price target of $60.00.

Get Our Latest Stock Analysis on SNY

Sanofi Trading Down 0.9 %

NASDAQ:SNY opened at $58.60 on Thursday. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $54.22 and a 200-day simple moving average of $52.89. The company has a market capitalization of $148.72 billion, a PE ratio of 23.53, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNYGet Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYFree Report).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.